HomeCompareACRX vs GBDC

ACRX vs GBDC: Dividend Comparison 2026

ACRX yields 232.56% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACRX wins by $272.82M in total portfolio value
10 years
ACRX
ACRX
● Live price
232.56%
Share price
$0.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$293.67M
Annual income
$159,094,488.39
Full ACRX calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — ACRX vs GBDC

📍 ACRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACRXGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACRX + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACRX pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACRX
Annual income on $10K today (after 15% tax)
$19,767.44/yr
After 10yr DRIP, annual income (after tax)
$135,230,315.13/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, ACRX beats the other by $121,247,191.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACRX + GBDC for your $10,000?

ACRX: 50%GBDC: 50%
100% GBDC50/50100% ACRX
Portfolio after 10yr
$157.26M
Annual income
$87,772,611.11/yr
Blended yield
55.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ACRX right now

ACRX
Analyst Ratings
10
Buy
6
Hold
1
Sell
Consensus: Buy
Altman Z
-22.3
Piotroski
4/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACRX buys
0
GBDC buys
0
No recent congressional trades found for ACRX or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACRXGBDC
Forward yield232.56%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$293.67M$20.85M
Annual income after 10y$159,094,488.39$16,450,733.83
Total dividends collected$278.92M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: ACRX vs GBDC ($10,000, DRIP)

YearACRX PortfolioACRX Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$33,956$23,255.81$12,492$1,791.70+$21.5KACRX
2$110,134$73,800.94$16,527$3,160.58+$93.6KACRX
3$341,552$223,709.32$23,588$5,904.90+$318.0KACRX
4$1,013,853$648,391.74$37,141$11,901.65+$976.7KACRX
5$2,883,575$1,798,752.11$66,205$26,463.38+$2.82MACRX
6$7,866,701$4,781,276.29$137,452$66,612.65+$7.73MACRX
7$20,607,870$12,190,500.18$342,372$195,298.53+$20.27MACRX
8$51,895,877$29,845,455.63$1,053,292$686,954.33+$50.84MACRX
9$125,770,153$70,241,564.71$4,111,439$2,984,416.95+$121.66MACRX
10$293,668,552$159,094,488.39$20,849,974$16,450,733.83+$272.82MACRX

ACRX vs GBDC: Complete Analysis 2026

ACRXStock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

Full ACRX Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ACRX vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACRX vs SCHDACRX vs JEPIACRX vs OACRX vs KOACRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.